-
Apr 17, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 17, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that...
-
Apr 11, 2007
CAMBRIDGE, Mass., Apr 11, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that...
-
Mar 13, 2007A proprietary small molecule multi-target inhibitor, CUDC-101 is being developed to target EGFR and another clinically validated cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 14, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that it...
-
Feb 14, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 14, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focusing on signaling pathway drug technologies to create new medicines primarily for...
-
Feb 1, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2007--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will...